Indium (111In) capromab pendetide

From WikiMD's WELLNESSPEDIA


Indium (111In) capromab pendetide













CAS Number 151763-64-3



ChemSpider none





Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]

Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]

References[edit]

  1. 1.0 1.1 "Indium-111 capromab pendetide in the management of recurrent prostate cancer".Expert Review of Anticancer Therapy.2008;8(2)
    175–81.doi:10.1586/14737140.8.2.175.PMID:18279057.
  2. WHO Drug Information
  3. Kahn, Daniel."A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy".Cancer Biotherapy & Radiopharmaceuticals.1999;14(2)
    99.doi:10.1089/cbr.1999.14.99.





Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.